GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Guardant Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$157.88−0.72 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $20.98B
- P/E (TTM)
- –
- Dividend yield
- –
Guardant Health, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | $683.60M | $542.83M | $403.88M | – | – | – | – | – | – | 69.6% | +25.9% |
| Biopharma and data | $210.13M | $177.58M | $136.35M | – | – | – | – | – | – | 21.4% | +18.3% |
| Screening | $79.73M | $5.12M | $0 | – | – | – | – | – | – | 8.1% | +1456.0% |
| Licensing and other | $8.56M | $13.49M | $23.72M | – | – | – | – | – | – | 0.9% | -36.5% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $923.28M | $697.16M | $526.52M | $420.62M | $352.56M | $264.66M | $194.31M | $77.92M | $43.72M | 94.0% | +32.4% |
| International | $58.74M | $41.85M | $37.42M | $28.92M | $21.09M | $22.07M | $20.06M | $12.72M | $6.13M | 6.0% | +40.3% |
From the segment and revenue-disaggregation notes of Guardant Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.